Price range: $77.00 through $1,090.00
Exendin-4 (Exenatide) is a synthetic 39-amino acid peptide and potent GLP-1 receptor agonist originally derived from the saliva of the Gila monster . It enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying to improve glycemic control in type 2 diabetes . Available in research-grade quantities from 2mg to 1g for preclinical and laboratory applications.
Looking to buy Exenatide for your research? Our lab-verified >95% pure Exenatide (Exendin-4) peptide is trusted by researchers worldwide for metabolic, wound healing, and neuroprotection research studies. In stock – ready to ship within 24 hours.
✅ Lab-Tested >95% Purity (COA Included)
✅ GLP-1 Receptor Agonist
✅ 39-Amino-Acid Peptide
✅ Fast, Discreet Shipping Worldwide
✅ Trusted by Leading Research Institutions
Exenatide (also known as Exendin-4) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Derived from the saliva of the Gila monster lizard (Heloderma suspectum), Exenatide is a 39-amino-acid peptide that shares 53% homology with human GLP-1 but exhibits superior receptor binding affinity and resistance to enzymatic degradation .
When you buy Exenatide from Mega Protide, you’re getting a research-grade peptide that has been third-party tested for purity and potency. This Exenatide research peptide is widely used in metabolic, wound healing, and neuroprotection research.
| Parameter | Details |
|---|---|
| Sequence | H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ |
| Molecular Formula | C₁₈₄H₂₈₂N₅₀O₆₀S |
| Molecular Weight | ~4186.6 Da |
| CAS Number | 141732-76-5 |
| Synonyms | Exendin-4, Exenatide acetate, AC 2993, LY2148568 |
| Homology to Human GLP-1 | 53% |
| Form | Lyophilized powder (white to off-white) |
| Available Quantities | 2mg, 5mg, 10mg, 25mg, 50mg, 100mg, 200mg, 1g |
| Purity | >95% by HPLC |
| Storage | Desiccated at -20°C for long-term stability |
| Source | Synthetic (Gila monster saliva analog) |
Exenatide exerts its effects through GLP-1 receptor activation:
| Receptor | Mechanism | Effect |
|---|---|---|
| GLP-1 Receptor | Stimulates glucose-dependent insulin secretion | Reduced blood glucose |
| GLP-1 Receptor | Suppresses inappropriately elevated glucagon release | Reduced hepatic glucose output |
| GLP-1 Receptor | Slows gastric emptying | Improved postprandial glucose control |
| GLP-1 Receptor | Central appetite suppression | Reduced caloric intake |
| GLP-1 Receptor | Increases beta-cell proliferation | Potential beta-cell preservation |
Key Advantage: Exenatide was the first GLP-1 receptor agonist approved for clinical use, establishing the class as a cornerstone of diabetes therapy. It exhibits superior receptor binding affinity and resistance to enzymatic degradation compared to native GLP-1.
| Application | Research Focus | Status |
|---|---|---|
| Type 2 Diabetes | Glycemic control, insulin secretion, glucagon suppression | FDA-approved (Byetta®, Bydureon®) |
| Wound Healing | Angiogenesis, collagen production, fibroblast proliferation | Active research |
| Combination Therapies | Synergistic effects with stem cells for tissue regeneration | Preclinical research |
| Neuroprotection | Protective effects against glutamate-induced neurotoxicity | Preclinical research |
| Obesity Research | Appetite regulation, weight reduction, energy expenditure | Clinical research |
| Cardiovascular Research | CV risk reduction in high-risk patients | Clinical research |
| Parameter | Finding |
|---|---|
| Glycemic Control | HbA1c reductions of 0.8% to 1.5% in clinical trials |
| Weight Reduction | 2-5 kg weight loss through appetite suppression |
| Extended-Release Benefit | Additional glycemic benefit and improved adherence |
| GLP-1 Receptor Binding | Superior receptor binding affinity vs native GLP-1 |
| Enzymatic Resistance | Resistance to DPP-4 degradation |
| Wound Healing | Accelerates wound closure in acute and diabetic wound models |
| Neuroprotection | Protective effects against neurotoxicity in preclinical models |
| Study | Year | Finding |
|---|---|---|
| Bode B, et al. | 2011 | Exenatide efficacy in glycemic control (Am J Manag Care) |
| Byetta Clinical Trials | 2005 | First GLP-1 receptor agonist approved for type 2 diabetes |
| Bydureon Clinical Trials | 2011 | Once-weekly extended-release formulation approved |
| Wound Healing Studies | 2015+ | Promotes angiogenesis, collagen production, fibroblast proliferation |
| Neuroprotection Studies | 2020+ | Protective effects against glutamate-induced neurotoxicity |
| Stem Cell Combination Studies | 2020+ | Synergistic effects with adipose-derived stem cells |
📖 Over 15 years of peer-reviewed research support Exenatide research utility.
Add 1-2ml bacteriostatic water to the Exenatide vial
Gently swirl – do not shake
Refrigerate at 2-8°C
Use within 30 days of reconstitution
| Formulation | Dose | Frequency |
|---|---|---|
| Byetta® (Twice-Daily) | 5 mcg or 10 mcg | Twice daily |
| Bydureon® (Once-Weekly) | 2 mg | Once weekly |
| Research Use (Rodent) | 0.1-1.0 mg/kg | Once daily |
| Route | Subcutaneous injection | |
| Half-Life | ~2.4 hours (immediate release); extended (weekly) |
| Quantity | Application |
|---|---|
| 2mg, 5mg, 10mg, 25mg | Small-scale in vitro studies and assay development |
| 50mg, 100mg, 200mg | Medium-scale preclinical research |
| 1g | Large-scale research programs |
| Parameter | Details |
|---|---|
| Storage (Lyophilized) | Desiccated at -20°C for long-term stability |
| Storage (Reconstituted) | 2-8°C, use within 30 days |
| Form | White to off-white powder |
| Shipping | Room temperature or ice pack |
| Aspect | Details |
|---|---|
| Safety Profile | Over 15 years of clinical use; well-established safety profile |
| Common Side Effects | Gastrointestinal (nausea, vomiting, diarrhea) – typically diminish over time |
| Contraindications | Personal/family history of MTC, MEN 2, hypersensitivity |
| Warnings | Pancreatitis, gallbladder disease, hypoglycemia (with sulfonylureas/insulin) |
| Limitations | Not for type 1 diabetes; not for patients with severe renal impairment |
| Long-Term Data | Long-term safety and efficacy established |
| Advantage | Why It Matters |
|---|---|
| Lab-Verified >95% Purity | Third-party HPLC testing ensures quality and consistency |
| Multiple Quantities Available | 2mg to 1g options for various research protocols |
| COA Included | Full transparency with every Exenatide order |
| Fast Shipping | Orders processed within 24 hours |
| Discreet Packaging | Privacy guaranteed |
Exenatide (Exendin-4) is supplied for research and laboratory use only. Not for human consumption. Not for therapeutic or diagnostic use. Use only by qualified researchers in controlled laboratory settings. Not FDA-approved for human use outside approved clinical protocols.
| Weight | 2mg, 5mg, 10mg, 25mg, 50mg, 100mg, 200mg, 500mg, 1g |
|---|
Always available!
Comes with each order!
Get access to expert resources.
Reviews
There are no reviews yet.